As reported in Immuno-Oncology News by Ines Martins, PhD, treatment with sintilimab, Innovent‘s PD-1 inhibitor, induces high response rates in non-small cell lung cancer (NSCLC) patients who have failed at least one prior treatment, particularly in those with a high...